Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck And Pfizer Strike Generics Deals

by Rick Mullin
February 27, 2012 | A version of this story appeared in Volume 90, Issue 9

Merck & Co. and Brazil’s Supera Farma Laboratorios have formed a joint venture to market pharmaceuticals and branded generics in Brazil. The partners will initially market approximately 30 products across multiple therapeutic areas. Meanwhile, Pfizer and Shanghai-based Hisun Pharmaceutical have advanced plans for a joint venture to commercialize off-patent drugs in China and other markets. Pfizer will own 49% of its joint venture with Hisun and invest $295 million in it. Merck will own 51% of its joint venture with Supera. Financial details of that deal were not disclosed.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.